OncoDaily

OncoDaily Your daily dose of hope, inspiration, and information in the fight against cancer.
(1)

OncoDaily.com – your go-to destination for the latest news, insights, and patient stories from the world of oncology!

06/03/2026

Yvonne Awards 2026: Honoring Excellence in Oncology

The Yvonne Awards 2026 celebrated leaders whose work continues to shape the future of cancer care through science, service, mentorship, innovation, and global impact.

Natera served as the exclusive partner of the Yvonne Awards Ceremony and OncoDaily Reception.

This year’s honorees included:

Global Oncology: Syed Nabeel Zafar
Lifetime Achievement Award: Eduardo Cazap
Lifetime Achievement Award: Charles Balch
Humanitarian Award: Mohammad I. M. Hojouj
Community Oncology: Hannatu Ayuba Usman
Leadership: Herbert Loong
Voice of Oncology: Amol Akhade
Mentorship: Adrienne Waks
Community Oncology: Joanna Metzner-Sadurski
Pediatric Oncology: Emmanuella-Faith Amoako
Mentorship: Samvel Bardakhchyan
AI in Oncology Named by ZS: Caroline Chung
Breakthrough Research: Hasmukh Jain
Challenging the Status Quo: Nickhill Bhakta
Challenging the Status Quo: Ana Velazquez-Manana
AI in Oncology Named by ZS: Abhishek D. Garg

Held during the OncoDaily Party 2026 at Park West, Chicago, the ceremony honored the many people and ideas moving oncology forward across regions, disciplines, and generations.

ZS

06/03/2026

OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition Is Here🧬🎗

OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition brought together leading voices in sarcoma care for a focused live session in Chicago, highlighting the latest directions in diagnosis, biomarker testing, immunotherapy, T-cell receptor therapy, antibody–drug conjugates, and novel therapeutics.

Special thanks to
Eli Lilly and Company, the Foundational Partner of the event, and
US WorldMeds, the Bronze Sponsor, for supporting this program. 🔬✨

The session was co-chaired by Dr. Sandra D’Angelo and Dr. Herbert Loong, with expert talks from Dr. Robin Jones , Dr. Javier Martín-Broto, Dr. Sandra D’Angelo, and Dr. Herbert Loong.

From targeted therapies and biomarker-informed treatment to chemotherapy-IO combinations and emerging cellular and drug-based approaches, the discussion reflected how rapidly the sarcoma field is evolving.

A sincere thank you to our co-chairs, speakers, partners, and everyone who joined us during ASCO 2026 for this important conversation on the future of sarcoma care.

ROSELLA Trial at ASCO 2026: Relacorilant Improves OS in Ovarian CancerThe ROSELLA trial brought a new mechanism to the A...
06/03/2026

ROSELLA Trial at ASCO 2026: Relacorilant Improves OS in Ovarian Cancer

The ROSELLA trial brought a new mechanism to the ASCO 2026 stage in one of oncology’s most stubborn settings: platinum-resistant ovarian cancer, where chemotherapy options are limited and survival has changed little in years. Presented by Lucy Gilbert, MD, MSc from McGill University Health Centre, Montreal, the analysis reported final overall survival (OS) results — and asked a question that matters to every patient facing this diagnosis: can adding a glucocorticoid receptor antagonist to chemotherapy help them live longer?

Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist designed to restore tumor sensitivity to chemotherapy-induced cell death. ROSELLA tested whether combining it with weekly nab-paclitaxel could outperform nab-paclitaxel alone — the most active single-agent chemotherapy in this disease — and the trial was designed around the two endpoints that define a meaningful advance: progression-free survival and overall survival.

Read more:
https://oncodaily.com/trial-updates/rosella-trial-asco-2026

25 Posts Not To Miss From ASCO 2026 Day 4The Day 4 of ASCO 2026 continued the momentum of innovation and collaboration i...
06/03/2026

25 Posts Not To Miss From ASCO 2026 Day 4

The Day 4 of ASCO 2026 continued the momentum of innovation and collaboration in oncology, with a focus on refining treatment strategies and addressing key challenges in cancer care. Sessions highlighted ongoing research, practical insights, and the integration of new therapies into clinical practice. Discussions emphasized the importance of evidence-based approaches to improve patient outcomes and foster sustainable advancements in the field.

Read here:
https://oncodaily.com/not-to-miss/asco26-513975

The Yvonne Awards Ceremony by OncoDaily Was Truly Oscar-Worthy - Amalya SargsyanRed carpet, beautiful dresses, oncologis...
06/02/2026

The Yvonne Awards Ceremony by OncoDaily Was Truly Oscar-Worthy - Amalya Sargsyan

Red carpet, beautiful dresses, oncologists, researchers, leaders, and of course, the greatest reception.

It was such an honor to co-present the Breakthrough Research Award with a very special person, Dr. Garo Armen, scientist, entrepreneur, philanthropist, global leader, and co-founder and CEO of Agenus.

Read more:
https://oncodaily.com/voices/amalya-sargsyan-513777

Journal Club with Scott – ResonanceWe look forward to seeing you every Friday at 9 am ET to enjoy lively discussion of l...
06/02/2026

Journal Club with Scott – Resonance

We look forward to seeing you every Friday at 9 am ET to enjoy lively discussion of leukemia and supportive care topics.

Date: June 5, 2026
Time: 05:00 PM – 06:00 PM AMT (09:00 AM – 10:00 AM ET)
Presenter: Scott Howard
Organizer: ALRCaN Global/Resonance Health

Yeolyan Hematology and Oncology Center, Ministry of Health of Armenia

Read more:
https://oncodaily.com/voices/resonance-511169

Is RAS No Longer Undruggable? Discussions on RASolute Trial That Earned Standing Ovation at ASCO26The Phase III RASolute...
06/02/2026

Is RAS No Longer Undruggable? Discussions on RASolute Trial That Earned Standing Ovation at ASCO26

The Phase III RASolute 302 trial data presented at ASCO 2026 has sparked widespread discussion across digital oncology platforms. Evaluating the multi-selective RAS(ON) inhibitor daraxonrasib in previously treated metastatic pancreatic cancer, the trial earned a rare standing ovation for nearly doubling median overall survival to 13.2 months. Digital discourse is heavily focused on whether these unprecedented results officially shatter the “undruggable” status of the RAS oncogene, with clinicians online actively debating how quickly this breakthrough will reshape the global standard of care.

Read here:
https://oncodaily.com/voices/rasolute-513272

30 Posts Not To Miss From ASCO 2026 Day 3The Annual Meeting of the American Society of Clinical Oncology (ASCO) is a cor...
06/01/2026

30 Posts Not To Miss From ASCO 2026 Day 3

The Annual Meeting of the American Society of Clinical Oncology (ASCO) is a cornerstone event in oncology, uniting clinicians, researchers, and industry leaders to shape the future of cancer care. On Day 3 of ASCO 2026, the focus shifted to pivotal discussions on cutting-edge treatments, emerging research, and collaborative solutions to advance global oncology. The day highlighted transformative insights that are redefining standards in cancer therapy and patient outcomes.

Read here:
https://oncodaily.com/not-to-miss/asco-not-to-miss-512985

Address

Boston, MA

Telephone

+19787174884

Website

Alerts

Be the first to know and let us send you an email when OncoDaily posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to OncoDaily:

Shortcuts

Share

Category